Noxopharm Ltd. (AU:NOX) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Noxopharm Limited, an Australian biotech firm listed on ASX (NOX), has released its corporate governance statement and Appendix 4G for the fiscal year 2024, highlighting its dedication to innovation in cancer and inflammation treatments, and its ownership stake in Nyrada Inc, another company specializing in novel therapies. The documents, confirming compliance with corporate governance standards, are available on the company’s website. Noxopharm is known for developing proprietary drugs using two main technology platforms and for enhancing mRNA vaccines.
For further insights into AU:NOX stock, check out TipRanks’ Stock Analysis page.